State Board of Administration of Florida Retirement System Acquires 2,291 Shares of Thermo Fisher Scientific Inc. (TMO)

State Board of Administration of Florida Retirement System raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.4% during the second quarter, HoldingsChannel reports. The institutional investor owned 552,868 shares of the medical research company’s stock after acquiring an additional 2,291 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Thermo Fisher Scientific were worth $114,521,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. FNY Investment Advisers LLC acquired a new position in Thermo Fisher Scientific during the second quarter valued at approximately $103,000. Horrell Capital Management Inc. acquired a new position in Thermo Fisher Scientific during the second quarter valued at approximately $104,000. Johnson Financial Group Inc. lifted its position in Thermo Fisher Scientific by 2,608.7% during the first quarter. Johnson Financial Group Inc. now owns 623 shares of the medical research company’s stock valued at $129,000 after buying an additional 600 shares in the last quarter. Edge Wealth Management LLC lifted its position in Thermo Fisher Scientific by 8,077.8% during the second quarter. Edge Wealth Management LLC now owns 736 shares of the medical research company’s stock valued at $152,000 after buying an additional 727 shares in the last quarter. Finally, Private Capital Group LLC lifted its position in Thermo Fisher Scientific by 57.3% during the first quarter. Private Capital Group LLC now owns 865 shares of the medical research company’s stock valued at $179,000 after buying an additional 315 shares in the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

TMO opened at $231.42 on Friday. The company has a market cap of $93.95 billion, a PE ratio of 22.53, a PEG ratio of 1.70 and a beta of 1.13. Thermo Fisher Scientific Inc. has a 52-week low of $170.07 and a 52-week high of $236.29. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.11 and a current ratio of 1.58.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 25th. The medical research company reported $2.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.63 by $0.12. The company had revenue of $6.08 billion for the quarter, compared to analyst estimates of $5.90 billion. Thermo Fisher Scientific had a net margin of 10.36% and a return on equity of 16.28%. The business’s quarterly revenue was up 21.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.30 earnings per share. equities research analysts predict that Thermo Fisher Scientific Inc. will post 10.98 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 15th. Stockholders of record on Monday, September 17th will be paid a dividend of $0.17 per share. The ex-dividend date of this dividend is Friday, September 14th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is currently 7.17%.

TMO has been the topic of a number of recent research reports. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $240.00 price target on the stock in a research report on Monday, April 30th. ValuEngine lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, June 20th. Morgan Stanley lifted their price objective on shares of Thermo Fisher Scientific from $230.00 to $233.00 and gave the company an “overweight” rating in a research note on Friday, July 13th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and set a $300.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 26th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Thermo Fisher Scientific currently has an average rating of “Buy” and an average target price of $239.08.

In related news, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction on Monday, June 4th. The shares were sold at an average price of $212.00, for a total value of $530,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, June 13th. The stock was sold at an average price of $217.71, for a total transaction of $10,885,500.00. Following the completion of the sale, the chief executive officer now owns 272,122 shares of the company’s stock, valued at approximately $59,243,680.62. The disclosure for this sale can be found here. Insiders have sold 168,256 shares of company stock worth $37,629,201 in the last quarter. Insiders own 0.49% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Further Reading: Using the New Google Finance Tool

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply